[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586967":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":27,"studyPopulation":28,"armGroups":29,"interventions":24,"overallOfficials":33,"centralContacts":38,"locations":24,"responsibleParty":44,"collaborators":47,"id":50,"slug":24,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":24,"enrollmentInfo":58,"targetDuration":61,"studyType":62,"phases":24,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":71,"whyStopped":24,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":24},{"fullName":5,"class":6},"Ospedale San Raffaele","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":18},[9],{"measure":10,"description":11,"timeFrame":12},"Frequency and cytotoxic activity of patient-specific tumor-reactive T cells.","The outcome will be evaluated by measuring the percentage of tumor-reactive T cells expressing activation markers (e.g., CD137, CD107a) via flow cytometry. Cytotoxic activity will be assessed through a tumor-killing assay, quantified as the percentage of tumor cell death measured by microscopy and flow cytometry.","1-30 months",[14],{"measure":15,"description":16,"timeFrame":17},"Expression of activation, differentiation, and exhaustion markers in generated T cell product.","The outcome will be evaluated by measuring the percentage of T cells expressing activation (e.g., CD137, CD107a), differentiation (e.g., CD45RA, CCR7), and exhaustion (e.g., PD-1, TIM-3) markers via flow cytometry.","12-30 months",[19],{"measure":20,"description":21,"timeFrame":22},"Time required for T cell generation and functional assessment.","The outcome will be evaluated by measuring the time (in days) required to generate tumor-reactive T cells and assessing their functionality through activation marker expression (e.g., CD137, CD107a) and cytotoxic activity via flow cytometry.","18-30 months",{"allocation":24,"interventionModel":24,"interventionModelDescription":24,"primaryPurpose":24,"observationalModel":25,"timePerspective":26,"maskingInfo":24},null,"CASE_ONLY","PROSPECTIVE","This study seeks to advance patient-specific cancer immunotherapy, through the ex-vivo generation of tumor-specific T cells recognizing and targeting tumor-specific mutations.\n\nThe study will enroll 20 adult patients with a diagnosis of non-small cell lung cancer, including those with lymph node involvement. Biological samples, including tumor and healthy lung tissue, as well as peripheral blood, will be collected pre-surgery and pre-treatment. The establishment of this sample collection will enable the detailed study of tumor-specific immune responses in non-small cell lung cancer.","The study population includes adult patients diagnosed with non-small cell lung cancer. Individuals of diverse gender, age, and ethnicity will be included, specifically those with stage I-II and III non-small cell lung cancer, including cases with lymph node involvement.",[30],{"label":31,"type":24,"description":32,"interventionNames":24},"Non-small cell lung cancer (NSCLC) patients","Adult subjects with diagnosis of non-small cell lung cancer (NSLC) that could undergo surgery or neo-adjuvant treatment.",[34],{"name":35,"affiliation":36,"role":37},"Chiara M Cattaneo, PhD","IRCCS Ospedale San Raffaele","PRINCIPAL_INVESTIGATOR",[39],{"name":35,"role":40,"phone":41,"phoneExt":42,"email":43},"CONTACT","+39022643","4712","cattaneo.chiara@hsr.it",{"type":37,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Chiara Maria Cattaneo","PhD",[48],{"name":49,"class":6},"Fondazione Umberto Veronesi","100586967",false,"NCT06922266","Personalizing Adoptive Cell Transfer for Solid Tumors: Towards a New Patient-tailored Treatment Option","Chewbacca","Inclusion Criteria:\n\n* Participant is willing and able to provide informed consent for participation in the study.\n* Age: Adults aged 18 years or older.\n* Diagnosis: non-small cell lung cancer (Stage I-II, III), with or without lymph node involvement, ideally with sufficient tumor burden to provide adequate tissue for analysis. In accordance with good clinical practice, patients with early-stage disease will undergo direct surgery, whereas patients with advanced-stage disease will receive neoadjuvant treatment followed by surgery.\n* Ability to attend scheduled follow-up visits, if applicable, for additional peripheral blood sample collection during treatment.\n\nExclusion Criteria:\n\n* Presence of any active infection or underlying condition that could compromise the safety of tissue and blood sampling.\n* Prior history of another malignancy that might interfere with data interpretation related to non-small cell lung cancer progression and immune response.\n* Any current use of immunosuppressive medications (e.g., high-dose steroids) which might alter immune response assessments, except as part of non-small cell lung cancer treatment.\n* Pregnancy and breastfeeding","ALL","18 Years",{"count":59,"type":60},20,"ESTIMATED","4 Years","OBSERVATIONAL","This is a monocentric prospective observational study. This study will include patients with a diagnosis of non-small cell lung cancer for the collection of blood and tissue specimens.",[65],"Carcinoma, Non-Small-Cell Lung",[67,68,69,70],"Immunotherapy","Precision Oncology","Lung cancer","Adoptive Cell Transfer","NOT_YET_RECRUITING","2025-04-03",{"date":74,"type":75},"2025-04-10","ACTUAL",{"date":77,"type":60},"2025-05-01",{"date":79,"type":60},"2029-04-30",{"name":5,"class":6}]